Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis cream takes on old standby in Head-to-Head trial

NCT ID NCT07635043

Disease control Sponsor: Pakistan Institute of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a newer cream called tapinarof works better than the standard betamethasone cream for mild-to-moderate plaque psoriasis. About 120 adults will use one of the two creams daily for up to 12 weeks. The main goal is to see how many people get at least a 75% improvement in their psoriasis symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tapinarof cream 1% and betamethasone dipropionate 0.05% cream
What this could lead to
If tapinarof works as well or better than betamethasone, it could offer a new topical treatment option for mild-to-moderate plaque psoriasis.
What could go wrong
This is a small, early-phase trial (120 people) that hasn't started yet. Results may not apply to everyone, and tapinarof might not prove superior or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years-65 years * Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity) * Disease duration of at least 6 months * Willing and able to provide written informed consent * Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies) Exclusion Criteria: * Severe psoriasis (BSA \>20% or requiring systemic therapy) * Pregnant and lactating mothers * Known hypersensitivity to Tapinarof or any of its excipients * Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis * Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment * History of malignancy or current active infection * Known hypersensitivity to betamethasone or Tapinarof * Use of powerful topical corticosteroids within two weeks previously

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis (PSO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis (PSO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pakistan institute of medical sciences(PIMS)

    Islamabad, Federal, 44000, Pakistan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.